文献类型：期刊文献

英文题名：Efficacy and safety of targeted drugs in advanced or metastatic gastric and gastroesophageal junction cancer: A network meta-analysis

作者：Gong, Hongxia[1,2,3];Su, Yun[1,2,3];Zhao, Lixia[4];Ma, Li[5];Zhang, Liying[1,2,3];Hou, Liangying[5];Li, Tingting[1,2,3];Niu, Shiwei[1,2,3];Zhang, Han[1,2,3];Li, Chenghao[1,2,3];Jin, Xiaojie[1,6];Ge, Long[5];Leng, Guangxian[7];Liu, Yongqi[1,2,3]

第一作者：龚红霞;Gong, Hongxia

通信作者：Liu, YQ[1];Leng, GX[2]

机构：[1]Gansu Univ Chinese Med, Prov Level Key Lab Mol Med Major Dis & Study Prev, Lanzhou, Gansu, Peoples R China;[2]Gansu Univ Chinese Med, Basic Med Coll, 35 Dingxi East Rd, Lanzhou 730000, Gansu, Peoples R China;[3]Chinese Minist Educ & Gansu Prov, Key Lab Dunhuang Med & Transformat, Lanzhou, Gansu, Peoples R China;[4]Gansu Univ Chinese Med, Coll Nursing, Lanzhou, Gansu, Peoples R China;[5]Lanzhou Univ, Sch Publ Hlth, Dept Social Med & Hlth Management, Lanzhou, Gansu, Peoples R China;[6]Gansu Univ Chinese Med, Coll Pharm, Lanzhou, Gansu, Peoples R China;[7]Lanzhou Univ, Clin Med Coll 2, 82 Cuiying Gate, Lanzhou 730000, Gansu, Peoples R China

第一机构：甘肃中医药大学

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Basic Med Coll, 35 Dingxi East Rd, Lanzhou 730000, Gansu, Peoples R China;[2]corresponding author), Lanzhou Univ, Clin Med Coll 2, 82 Cuiying Gate, Lanzhou 730000, Gansu, Peoples R China.|[107351d2d02a88e1f325f]甘肃中医药大学基础医学院（敦煌医学研究所）;[10735]甘肃中医药大学;

年份：2022

卷号：47

期号：4

起止页码：493

外文期刊名：JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

收录：;Scopus(收录号：2-s2.0-85119180129);WOS:【SCI-EXPANDED(收录号:WOS:000720073900001)】；

基金：This research was funded by the National Natural Science Foundation of China (Grant Number: 81660744 and 81960869), Provincial Key Talent Project (No. GZT 2020-9-1) and the Innovation Capacity Improvement Project of Colleges and Universities in Gansu Province (Grant Number 2020A--072)

语种：英文

外文关键词：gastric cancer; gastroesophageal junction cancer; network meta-analysis; targeted drugs

摘要：What is known and objective: An increasing number of targeted drugs have been used to treat advanced or metastatic gastric cancer (GC) and gastroesophageal junction cancer (GEJC). However, the optimal treatment efficacy of these drugs is still controversial. The aims of this study are to systematically summarize the efficacy and safety of current targeted drugs for advanced or metastatic GC and GEJC. Methods: PubMed, EmBase, Cochrane Library, Web of Science and ClinicalTrials were searched for double-blind randomized controlled trials (RCTs) on GC and GEJC up to December 2019. Additionally, we updated the literature search from Jan, 1, 2020 to September 30, 2021. Narrative and quantitative analysis were performed to analyse the efficacy and safety. STATA 15.1 was used to identify publication bias, and the SUCRA (surface under the cumulative ranking) curve was conducted to rank the treatments for each outcome. Results: A total of 27 RCTs with 9295 GC and GEJC patients treated by 19 drugs were included. SUCRA showed that regorafenib was the most likely to improve patients' progression-free survival (96.4%), followed by apatinib (90.7%), nivolumab (82.4%), everolimus (76.5%) and pertuzumab (68.5%). Meanwhile, apatinib (92.4%) was most likely to improve overall survival, followed by nivolumab (87.9%), regorafenib (72.5%), olaparib (67.7%) and lapatinib (63.2%). Additionally, neutropenia, diarrhoea and fatigue were the most common adverse events caused by these drugs, followed by pain, nausea, decreased appetite, anaemia and vomiting. What is new and conclusion: Regorafenib and nivolumab have higher efficacy and tolerability and are the most advantageous for advanced GC and GEJC. Moreover, apatinib has higher efficacy but lower tolerability. Everolimus and pertuzumab combined with chemotherapy have best secondary higher efficacy for progression-free survival and good tolerability. Lapatinib and olaparib combined with chemotherapy have moderate efficacy for overall survival and good tolerability.